Ignite Creation Date:
2024-05-05 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00476463
Status:
COMPLETED
Last Update Posted:
2016-02-22
First Post:
2007-05-20
Brief Title:
Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIVHBV Co-infection
Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Organization:
The HIV Netherlands Australia Thailand Research Collaboration
Study Overview
Official Title:
Virological and Clinical Anti-HBV Efficacy of Tenofovir and Emtricitabine in Antiretroviral Naive Patients With HIVHBV Co-infection
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Combination therapy with anti-HBV activity may both increase HBV suppression rates and reduce emergence of resistant strains Several new therapeutic agents are currently in development however combination therapy trials in the HBV-infected population have only recently commenced No such trials have been undertaken in the HIVHBV co-infected population
Detailed Description:
The primary study objective is to compare HBV DNA suppression to levels below the limit of detection 400 copiesml by week 48 in each treatment group Virological and clinical anti-HBV efficacy of tenofovir and emtricitabine in antiretroviral naive patients with HIVHBV co-infection
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None